REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men
About the study
The study objective is to compare water vapor thermotherapy with the REZŪM™ System to dual drug therapy for the treatment of symptomatic benign prostatic hyperplasia refractory to alpha-blocker monotherapy in sexually active men.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Benign Prostatic Hyperplasia (BPH)
Age (in years)
45+
Phase
Not Applicable
Participants needed
394
Est. Completion Date
Jul 31, 2026
Treatment type
Interventional
Sponsor
Boston Scientific Corporation
ClinicalTrials.gov identifier
NCT04838769
Study number
U0693
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?